Virtual Pharma Company

Client: Virtual Pharma Company

Challenge:

• Problematic formulation and analytical method
• Blinding issues with market leading comparator

Penn solution/ongoing support:

• Developed a suitable manufacturing process and re-built the analytical method
• Over-encapsulated market leading comparator and developed the analytical method to general appropriate stability data
• Support for three simultaneous phase III trials
• Average of 1,800 patients per trial
• Multi national trial – EU, US and ROW
• 64,000 monthly kits over two years
• Bespoke child resistant – senior friendly (CRSF) packaging solution
• Liaise with two CROs
• Liaise with two IVRS providers
• Penn arranged multiple global distribution depots